-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

SCI-7 Use of Minimal Residual Disease and Advances in Clinical Trials

Program: Scientific Program
Session: Getting the Most from Minimal Residual Disease
Hematology Disease Topics & Pathways:
biopsy, Technology and Procedures, genetic profiling, Clinically relevant, molecular testing, NGS
Sunday, December 6, 2020, 1:55 PM-2:00 PM

Davide Rossi, MD, PhD

Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Disclosures: Rossi: Abbvie: Honoraria, Research Funding; Gilead: Honoraria, Research Funding; Janssen: Honoraria, Research Funding; AstraZeneca: Honoraria, Research Funding.

See more of: Getting the Most from Minimal Residual Disease
See more of: Scientific Program
Previous Presentation | Next Presentation >>